Daptomycin Side Effects: Safety Signals and Warnings
Daptomycin safety concerns are compound-specific. The main listed side effects are CPK elevation and myopathy, Diarrhea, and Headache. The main warning signals are Do NOT use for pneumonia (inactivated by pulmonary surfactant), Monitor CPK weekly during therapy, and Dose adjustment required in renal impairment (CrCl <30 mL/min).
Direct Answer
Daptomycin (Cubicin) is FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and complicated skin infections. It is a first-line IV antibiotic with extensive Phase 3 data and a 20+ year clinical track record. For researchers studying gram-positive infection treatment, daptomycin is a validated standard-of-care option with high-quality evidence.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Evidence context
- MRSA bacteremia, right-sided endocarditis, complicated skin and soft tissue infections, gram-positive infection treatment
Reported Side Effects
- CPK elevation and myopathy
- Diarrhea
- Headache
- Insomnia
- Nausea and vomiting
- Eosinophilic pneumonia (rare)
- Peripheral neuropathy (rare)
Warnings
- Do NOT use for pneumonia (inactivated by pulmonary surfactant)
- Monitor CPK weekly during therapy
- Dose adjustment required in renal impairment (CrCl <30 mL/min)
- Not effective against gram-negative organisms
- Consider discontinuing statins during therapy to reduce myopathy risk
Known or Plausible Interactions
- HMG-CoA reductase inhibitors/statins (increased myopathy risk)
- Tobramycin (additive nephrotoxicity potential)
- Warfarin (monitor INR)
- Other nephrotoxic drugs (use with caution)
Regulatory Context
FDA-approved since 2003 (Cubicin). Prescription required. Available generically. Approved worldwide for complicated skin infections and S. aureus bacteremia. On the WHO Essential Medicines List.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | MRSA Bacteremia Treatment (Level A), Complicated Skin Infections (Level A), and CPK Elevation (Adverse) (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Daptomycin?
Daptomycin safety concerns are compound-specific. The main listed side effects are CPK elevation and myopathy, Diarrhea, and Headache. The main warning signals are Do NOT use for pneumonia (inactivated by pulmonary surfactant), Monitor CPK weekly during therapy, and Dose adjustment required in renal impairment (CrCl <30 mL/min).
What is the evidence level for Daptomycin?
Daptomycin is rated Level A. Its current research status is FDA Approved.
What is Daptomycin best known for?
MRSA bacteremia, right-sided endocarditis, complicated skin and soft tissue infections, gram-positive infection treatment.
Where can I read the full Daptomycin evidence review?
The full evidence review is available at https://examinepeptides.com/library/daptomycin.
Related Guides
How to Cite This Page
ExaminePeptides. "Daptomycin Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/daptomycin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.